Corticosteroids Treatment in Spinal Cord and Neuromuscular Disorders

[1]  David Choi,et al.  Traumatic Spinal Cord Injury—Repair and Regeneration , 2017, Neurosurgery.

[2]  A. Mukherjee,et al.  Therapy of NMO spectrum disorders , 2015, Annals of Indian Academy of Neurology.

[3]  S. Sarkhel,et al.  Author's response on “Neuropsychiatric profiles in patients with Alzheimer's disease and vascular dementia” , 2015, Annals of Indian Academy of Neurology.

[4]  R. Alp,et al.  Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-Year follow up , 2014, Clinical Neurology and Neurosurgery.

[5]  Jacques P. Brown,et al.  A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy , 2013, Allergy, Asthma & Clinical Immunology.

[6]  Beau B. Bruce,et al.  Safety of Prednisone for Ocular Myasthenia Gravis , 2012, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[7]  Stefano Tamburin,et al.  Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial , 2012, The Lancet Neurology.

[8]  A. V. van Norden,et al.  Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment , 2012, Neurology.

[9]  M. Bracken.  Steroids for acute spinal cord injury. , 2012, The Cochrane database of systematic reviews.

[10]  M. Dalakas.  Advances in the diagnosis, pathogenesis and treatment of CIDP , 2011, Nature Reviews Neurology.

[11]  T. Kiuchi,et al.  Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[12]  G. Parry,et al.  Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice , 2010, Journal of the peripheral nervous system : JPNS.

[13]  H. Jones,et al.  Ocular myasthenia gravis in a senior population: Diagnosis, therapy, and prognosis , 2010, Muscle & nerve.

[14]  A. V. van Norden,et al.  Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial , 2010, The Lancet Neurology.

[15]  M. Dalakas.  Immunotherapy of myositis: issues, concerns and future prospects , 2010, Nature Reviews Rheumatology.

[16]  N. Gilhus,et al.  Guidelines for treatment of autoimmune neuromuscular transmission disorders , 2006, European journal of neurology.

[17]  T. Brannagan.  Current treatments of chronic immune‐mediated demyelinating polyneuropathies , 2009, Muscle & nerve.

[18]  G. Parry,et al.  Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. , 2008, Archives of neurology.

[19]  M. Benatar,et al.  Treatment of ocular symptoms in myasthenia gravis , 2008, Neurology.

[20]  D. Richman,et al.  An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis , 2008, Neurology.

[21]  S. Sathasivam.  Steroids and immunosuppressant drugs in myasthenia gravis , 2008, Nature Clinical Practice Neurology.

[22]  M. Benatar,et al.  Evidence report : The medical treatment of ocular myasthenia ( an evidence-based review ) : Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2009 .

[23]  B. Kim,et al.  Clinical predictors of steroid-induced exacerbation in myasthenia gravis , 2006, Journal of Clinical Neuroscience.

[24]  I. Targoff,et al.  Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies: Analysis of 100 French Canadian Patients , 2005, Medicine.

[25]  A. Pestronk,et al.  Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. , 2005, Archives of neurology.

[26]  G. Burmester,et al.  Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. , 2004, Arthritis and rheumatism.

[27]  R. Hughes,et al.  Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. , 2004, The Cochrane database of systematic reviews.

[28]  J. King,et al.  Immunotherapy of Ocular Myasthenia Gravis Reduces Conversion to Generalized Myasthenia Gravis , 2003, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[29]  M. Dalakas,et al.  Therapeutic Approaches in Patients with Inflammatory Myopathies , 2003, Seminars in neurology.

[30]  R. Hohlfeld,et al.  Basic principles of immunotherapy for neurologic diseases. , 2003, Seminars in neurology.

[31]  M. Kupersmith,et al.  Development of generalized disease at 2 years in patients with ocular myasthenia gravis. , 2003, Archives of neurology.

[32]  R. Hughes,et al.  Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. , 2017, The Cochrane database of systematic reviews.

[33]  P. Tonali,et al.  Therapeutic options in ocular myasthenia gravis , 2001, Neuromuscular Disorders.

[34]  F. Mastaglia.  Treatment of autoimmune inflammatory myopathies. , 2000, Current opinion in neurology.

[35]  M. Agius.  Treatment of ocular myasthenia with corticosteroids: yes. , 2000, Archives of neurology.

[36]  P C O'Brien,et al.  The clinical course of neuromyelitis optica (Devic’s syndrome) , 1999, Neurology.

[37]  S. Rednic,et al.  The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis. , 1999, Advances in Experimental Medicine and Biology.

[38]  A. Lefvert,et al.  Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study , 1998, Acta neurologica Scandinavica.

[39]  F. Mastaglia,et al.  Treatment of inflammatory myopathies , 1997, Muscle & nerve.

[40]  H. Winn,et al.  Administration of Methylprednisolone for 24 or 48 Hours or Tirilazad Mesylate for 48 Hours in the Treatment of Acute Spinal Cord Injury Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial , 1997 .

[41]  A. Ropper,et al.  Chronic inflammatory demyelinating polyneuropathy , 1997, Neurology.

[42]  J. Dichgans,et al.  Ocular myasthenia gravis: response to long-term immunosuppressive treatment. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[43]  Hiroshige Nakamura,et al.  Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. , 1996, The Journal of thoracic and cardiovascular surgery.

[44]  M. Moster,et al.  Beneficial effects of corticosteroids on ocular myasthenia gravis. , 1996, Archives of neurology.

[45]  J. Albers,et al.  Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy , 1993, Neurology.

[46]  M. Joffe,et al.  Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. , 1993, The American journal of medicine.

[47]  M. Bracken,et al.  The Second National Acute Spinal Cord Injury Study. , 1990, Journal of neurotrauma.

[48]  R. Sergott,et al.  Factors influencing outcome of prednisone dose reduction in myasthenia gravis , 1991, Neurology.

[49]  L. Durelli,et al.  Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[50]  F. Frey,et al.  Clinical Pharmacokinetics of Prednisone and Prednisolone , 1990, Clinical pharmacokinetics.

[51]  J. Mendell,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. , 1989, Archives of neurology.

[52]  P. Tonali,et al.  Ocular myasthenia: diagnostic and therapeutic problems , 1988, Acta neurologica Scandinavica.

[53]  J. Mcleod,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. , 1987, Brain : a journal of neurology.

[54]  B. Green,et al.  Efficacy of methylprednisolone in acute spinal cord injury. , 1984, JAMA.

[55]  R. Dinapoli,et al.  Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment , 1982, Annals of neurology.

[56]  R. Schwartzman,et al.  ORAL CORTICOSTEROIDS IN THE TREATMENT OF OCULAR MYASTHENIA GRAVIS , 1976, Annals of the New York Academy of Sciences.

[57]  J. Daube,et al.  ALTERNATE‐DAY PREDNISONE: PRELIMINARY REPORT OF A DOUBLE‐BLIND CONTROLLED STUDY * , 1976, Annals of the New York Academy of Sciences.

[58]  P. Dyck,et al.  Chronic inflammatory polyradiculoneuropathy. , 1975, Mayo Clinic proceedings.

[59]  S. Fuchs,et al.  Myasthenia gravis and acetylcholine receptor. Effect of steroids in clinical course and cellular immune response to acetylcholine receptor. , 1975, Archives of neurology.

[60]  D. Drachman,et al.  Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. , 1974, The New England journal of medicine.

[61]  I. Cohen,et al.  Glucocorticoids and cellular immunity in vitro. Facilitation of the sensitization phase and inhibition of the effector phase of a lymphocyte anti-fibroblast reaction. , 1970 .

[62]  F. Mount.  CORTICOTROPIN IN TREATMENT OF OCULAR MYASTHENIA; A CONTROLLED CLINICAL TRIAL. , 1964, Archives of neurology.

[63]  H. F. Polley.  Present Therapeutic Status of Cortisone and its Derivatives, with Special Reference to Rheumatic Diseases* , 1956, British medical journal.

[64]  D. Grob,et al.  Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis and report of onset of myasthenia gravis during prolonged cortisone administration. , 1952, Bulletin of the Johns Hopkins Hospital.

[65]  C. Millikan,et al.  Clinical Evaluation of ACTH and Cortisone In Myasthenia Gravis , 1951, Neurology.

[66]  P. Hench,et al.  Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. , 1950, Archives of internal medicine.

[67]  P. Hench,et al.  The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. , 1949, Proceedings of the staff meetings. Mayo Clinic.